Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections

Four accepted presentations include a late-breaker featuring Phase
2 STRIVE trial data and three posters describing the activity of
rezafungin against fungal pathogens

SAN DIEGO–(BUSINESS WIRE)–May 23, 2018–
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that it will present four posters highlighting data from
preclinical studies and a clinical trial of rezafungin, its lead
antifungal product candidate, at the American Society for Microbiology
(ASM) Microbe 2018, being held June 7-11 in Atlanta. Cidara’s
presentations will …

READ FULL TEXT

Leave a Reply

Your email address will not be published.